Skip to main content

Neon Bloom increases authorized Common Stock and creates Series B Preferred Stock

Written by Customer Service on . Posted in Public Companies.

ORLANDO, Fla., Jan. 05, 2022 (GLOBE NEWSWIRE) — Neon Bloom, Inc. (OTC: NBCO), through its wholly owned subsidiary Bazelet Health Systems, Inc., is a professional healthcare organization leading cannabis science and the development of federally compliant, non-psychoactive cannabis products. On January 3, 2022, upon receiving consent from a majority of its voting shareholders, the Company amended its Articles of Incorporation to (i) increase its authorized shares of Common Stock to 750,000,000; and (ii) create a Series B Preferred stock of which it is authorized to issue up to 2,000,000 shares.

About: Bazelet™ is revolutionizing the field of cannabis genome engineering and sequencing and is deeply involved in the scientific, medical, and regulatory communities regarding the cannabis genus. The company is breeding from varieties that are registered and approved globally, including by the EU and AOSCA, and new plant genetics that utilize CRISPR-Cas9 to further advance our unprecedented cannabis genetics library. Bazelet leads the scientific, medical, consumer and regulatory communities with the world’s first patented, federally legal, non-psychoactive, therapeutic cannabis plants and ingredients.

Disclaimer: This Press Release is for informational purposes, contains forward-looking statements based on current expectations, forecasts, and assumptions with information available to us as of the date hereof and involve risks and uncertainties. This Press Release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Actual results may differ materially from those stated or implied in such forward-looking statements. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “would” or similar words. We assume no obligation to update the information included in this Press Release, whether a result of new information, future events or otherwise.

CONTACT: Robyn Frick
EMAIL: media@bazelethealth.com
WEBSITE: www.bazelethealth.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.